Abstract |
This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in non-small cell lung cancer patients in terms of their response and prognosis. In total, 377 patients agreed to participate in our study, and all of them received platinum-based combination chemotherapy between January 2008 and January 2009. The relative cDNA quantitation for RRM1 and BRCA1 was conducted using a fluorescence-based, real-time detection method, using β-actin as a reference gene. The average age of the 377 patients was 64.6 years (range: 25.5-86.4 years), including 269 men and 108 women. Patients with high RRM1 expression benefited more from a platinum-containing regimen, and patients with high BRCA1 expression showed a high response rate to a platinum-containing regimen and reduced disease progression. Patients with high RRM1 expression were associated with a longer progression-free survival (PFS) and overall survival (OS) than those with low expression, and the hazard ratios (HRs) (95% confidence interval (CI)) were 0.67 (0.32-0.91) and 0.54 (0.30-0.95), respectively. Patients with high BRCA1 expression showed longer PFS and OS compared to those with low expression, and the HRs (95%CI) were 0.54 (0.30-0.95) and 0.62 (0.32-0.93), respectively. These results could be used in personalized chemotherapy decisions and to increase the response rate and prolonged survival, and could encourage exploration of the predictive value of other genes.
|
Authors | J G Liang, Z Y Jin, X D Gao, M R Te, L H Ge, C L Wang |
Journal | Genetics and molecular research : GMR
(Genet Mol Res)
Vol. 13
Issue 3
Pg. 5292-8
(Jul 24 2014)
ISSN: 1676-5680 [Electronic] Brazil |
PMID | 25078585
(Publication Type: Journal Article)
|
Chemical References |
- BRCA1 Protein
- BRCA1 protein, human
- Biomarkers, Pharmacological
- RNA, Messenger
- Tumor Suppressor Proteins
- Deoxycytidine
- Vinblastine
- RRM1 protein, human
- Ribonucleoside Diphosphate Reductase
- Paclitaxel
- Cisplatin
- Vinorelbine
- Gemcitabine
|
Topics |
- Adenocarcinoma
(drug therapy, genetics, mortality, pathology)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- BRCA1 Protein
(genetics, metabolism)
- Biomarkers, Pharmacological
(metabolism)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics, mortality, pathology)
- Cisplatin
(administration & dosage)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Female
- Gene Expression
- Humans
- Lung Neoplasms
(drug therapy, genetics, mortality, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Paclitaxel
(administration & dosage)
- RNA, Messenger
(genetics, metabolism)
- Ribonucleoside Diphosphate Reductase
- Survival Analysis
- Treatment Outcome
- Tumor Suppressor Proteins
(genetics, metabolism)
- Vinblastine
(administration & dosage, analogs & derivatives)
- Vinorelbine
- Gemcitabine
|